{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T11:35:34Z","timestamp":1648899334343},"reference-count":45,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.transproceed.2010.06.018","type":"journal-article","created":{"date-parts":[[2010,11,20]],"date-time":"2010-11-20T09:24:13Z","timestamp":1290245053000},"page":"3647-3651","source":"Crossref","is-referenced-by-count":2,"title":["Factors Associated With Sustained Virological Response in Liver Transplant Recipients With Recurrent Hepatitis C"],"prefix":"10.1016","volume":"42","author":[{"given":"A.A.","family":"Pillai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.E.","family":"Rinella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Levitsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2010.06.018_bib1","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1053\/jlts.2003.50248","article-title":"The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients","volume":"9","author":"Gane","year":"2003","journal-title":"Liver Transpl"},{"key":"10.1016\/j.transproceed.2010.06.018_bib2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/01.qco.0000136934.06039.01","article-title":"Natural history of hepatitis C following liver transplantation","volume":"17","author":"Rodriguez-Luna","year":"2004","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.transproceed.2010.06.018_bib3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/lt.500060111","article-title":"Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: persistent elevation of serum transminase levels versus necroinflammatory activity","volume":"6","author":"Pelletier","year":"2000","journal-title":"Liver Transpl"},{"key":"10.1016\/j.transproceed.2010.06.018_bib4","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/hep.510290122","article-title":"High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes","volume":"29","author":"Prieto","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.transproceed.2010.06.018_bib5","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJM199603283341302","article-title":"Long-term outcome of hepatitis C infection after liver transplantation","volume":"334","author":"Gane","year":"1996","journal-title":"N Engl Med"},{"key":"10.1016\/j.transproceed.2010.06.018_bib6","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0016-5085(99)70454-3","article-title":"European collaborative study on factors influencing outcome after liver transplantation for hepatitis C","volume":"117","author":"Feray","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.transproceed.2010.06.018_bib7","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1053\/gast.2002.32418","article-title":"The association between hepatitis C infection and survival after orthotopic liver transplantation","volume":"122","author":"Forman","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.transproceed.2010.06.018_bib8","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/lt.21117","article-title":"A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation","volume":"13","author":"Yilmaz","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1016\/j.transproceed.2010.06.018_bib9","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.jhep.2004.06.029","article-title":"Fibrosis progression after liver transplantation in patients with recurrent hepatitis C","volume":"41","author":"Neumann","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.transproceed.2010.06.018_bib10","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1053\/jhep.2003.50231","article-title":"All liver recipients benefit from the protocol 10-year liver biopsies","volume":"37","author":"Sebagh","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.transproceed.2010.06.018_bib11","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","article-title":"Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups","volume":"349","author":"Poynard","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.transproceed.2010.06.018_bib12","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/hep.510280632","article-title":"Prognosis of chronic hepatitis C: results of a large, prospective cohort study","volume":"28","author":"Niederau","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.transproceed.2010.06.018_bib13","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jhep.2008.05.002","article-title":"Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin","volume":"49","author":"Berenguer","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.transproceed.2010.06.018_bib14","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1600-6143.2007.02126.x","article-title":"Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation","volume":"8","author":"Berenguer","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2010.06.018_bib15","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jhep.2006.10.017","article-title":"Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation","volume":"46","author":"Picciotto","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.transproceed.2010.06.018_bib16","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1053\/jhep.2003.50106","article-title":"Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy","volume":"37","author":"Berg","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.transproceed.2010.06.018_bib17","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jhep.2008.07.013","article-title":"Treatment predictors of a sustained virologic response in hepatitis B and C","volume":"49","author":"Kau","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.transproceed.2010.06.018_bib18","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1111\/j.1572-0241.2002.05995.x","article-title":"Contribution of obesity to hepatitis C- related fibrosis progression","volume":"97","author":"Ortiz","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.transproceed.2010.06.018_bib19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.510290401","article-title":"Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis","volume":"29","author":"Hourigan","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.transproceed.2010.06.018_bib20","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1053\/jhep.2003.50350","article-title":"High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C","volume":"38","author":"Bressler","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.transproceed.2010.06.018_bib21","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/hep.21239","article-title":"Impact of obesity on treatment of chronic hepatitis C","volume":"43","author":"Charlton","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.transproceed.2010.06.018_bib22","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/gut.2004.050302","article-title":"Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C","volume":"54","author":"Fartoux","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.transproceed.2010.06.018_bib23","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1053\/j.gastro.2003.08.032","article-title":"Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]","volume":"125","author":"Hui","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.transproceed.2010.06.018_bib24","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1053\/j.gastro.2004.12.049","article-title":"Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients","volume":"128","author":"Romero-Gomez","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.transproceed.2010.06.018_bib25","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/gut.2004.059873","article-title":"Insulin resistance and steatosis in hepatitis C virus infection","volume":"54","author":"Zekry","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.transproceed.2010.06.018_bib26","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.cgh.2008.02.034","article-title":"Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection","volume":"6","author":"Hanouneh","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.transproceed.2010.06.018_bib27","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.diabres.2006.07.008","article-title":"Hepatitis C, metabolic syndrome, and inflammatory markers: results from the Third National Health and Nutrition Examination Survey [NHANES III]","volume":"75","author":"Shaheen","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"issue":"suppl 2","key":"10.1016\/j.transproceed.2010.06.018_bib28","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1002\/lt.21644","article-title":"Virology and pathogenesis of hepatitis C virus recurrence","volume":"14","author":"Ramirez","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1016\/j.transproceed.2010.06.018_bib29","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1053\/jhep.2000.17924","article-title":"Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation","volume":"32","author":"Berenguer","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.transproceed.2010.06.018_bib30","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1053\/jlts.2001.27084","article-title":"Analysis of causes of death in liver transplant recipients who survived more than 3 years","volume":"7","author":"Pruthi","year":"2001","journal-title":"Liver Transpl"},{"key":"10.1016\/j.transproceed.2010.06.018_bib31","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","article-title":"Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients","volume":"112","author":"Fattovich","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.transproceed.2010.06.018_bib32","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jhep.2003.12.015","article-title":"Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination","volume":"40","author":"Dumortier","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.transproceed.2010.06.018_bib33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jhep.2005.02.015","article-title":"Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation","volume":"43","author":"Castells","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.transproceed.2010.06.018_bib34","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/lt.20737","article-title":"Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C","volume":"12","author":"Berenguer","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.transproceed.2010.06.018_bib35","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1111\/j.1600-6143.2006.01470.x","article-title":"Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose PEG- interferon and ribavirin","volume":"6","author":"Oton","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2010.06.018_bib36","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1053\/j.gastro.2007.03.041","article-title":"Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study","volume":"132","author":"Carrion","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.transproceed.2010.06.018_bib37","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/lt.20883","article-title":"Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation","volume":"12","author":"Fernandez","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.transproceed.2010.06.018_bib38","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/lt.21121","article-title":"Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence","volume":"13","author":"Sharma","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1016\/j.transproceed.2010.06.018_bib39","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/01.tp.0000225827.18034.be","article-title":"Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin","volume":"82","author":"Neumann","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2010.06.018_bib40","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1111\/j.1600-6143.2005.00976.x","article-title":"Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C","volume":"5","author":"Bizollon","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2010.06.018_bib41","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/01.tp.0000250575.92788.aa","article-title":"Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy)","volume":"83","author":"Bahra","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2010.06.018_bib42","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/TP.0b013e31817c0e20","article-title":"Sustained clearance of serum hepatitis C virus-RNA independently predicts long-term survival in liver transplant patients with recurrent hepatitis C","volume":"86","author":"Kornberg","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2010.06.018_bib43","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/lt.21524","article-title":"The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation","volume":"14","author":"Hanouneh","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1016\/j.transproceed.2010.06.018_bib44","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/j.1600-6143.2009.02642.x","article-title":"Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C","volume":"9","author":"Veldt","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2010.06.018_bib45","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.transproceed.2006.02.060","article-title":"The impact of nonalcoholic fatty liver disease and the metabolic syndrome on progression of fibrosis in patients with recurrent HCV after liver transplantation","volume":"38","author":"Mindikoglu","year":"2006","journal-title":"Transplant Proc"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134510012716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134510012716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T19:00:15Z","timestamp":1544122815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134510012716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0041134510012716"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2010.06.018","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}